Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Commercial Sponsor
Hoffmann-La Roche
Summary
Eligible patients will be randomised to receive intravenous atezolizumab and tiragolumab in combination, or intravenous durvalumab alone, on specified days of each 28-day cycle for a maximum 13 cycles.